Red Blood Cell Homeostasis and Altered Vesicle Formation in Patients With Paroxysmal Nocturnal Hemoglobinuria by Freitas Leal, J.K. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/204047
 
 
 
Please be advised that this information was generated on 2019-07-08 and may be subject to
change.
Frontiers in Physiology | www.frontiersin.org 1 May 2019 | Volume 10 | Article 578
ORIGINAL RESEARCH
published: 15 May 2019
doi: 10.3389/fphys.2019.00578
Edited by: 
Paola Bianchi, 
IRCCS Ca’Granda Foundation 
Maggiore Policlinico Hospital, Italy
Reviewed by: 
Mauro Magnani, 
University of Urbino Carlo Bo, Italy
Marianna H. Antonelou, 
National and Kapodistrian 
University of Athens, Greece
*Correspondence: 
Giel Bosman 
giel.bosman@radboudumc.nl
Specialty section: 
This article was submitted to 
Red Blood Cell Physiology, 
a section of the journal 
Frontiers in Physiology
Received: 20 February 2019
Accepted: 24 April 2019
Published: 15 May 2019
Citation:
Freitas Leal JK, Preijers F, Brock R, 
Adjobo-Hermans M and Bosman G 
(2019) Red Blood Cell Homeostasis 
and Altered Vesicle Formation in 
Patients With Paroxysmal 
Nocturnal Hemoglobinuria.
Front. Physiol. 10:578.
doi: 10.3389/fphys.2019.00578
Red Blood Cell Homeostasis and 
Altered Vesicle Formation in  
Patients With Paroxysmal  
Nocturnal Hemoglobinuria
Joames K. Freitas Leal1, Frank Preijers2, Roland Brock1, Merel Adjobo-Hermans1 and 
Giel Bosman1*
1Department of Biochemistry, Radboud University Medical Center, Nijmegen, Netherlands, 2Laboratory for Hematology, 
Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, Netherlands
A subset of the red blood cells (RBCs) of patients with paroxysmal nocturnal hemoglobinuria 
(PNH) lacks GPI-anchored proteins. Some of these proteins, such as CD59, inhibit 
complement activation and protect against complement-mediated lysis. This pathology 
thus provides the possibility to explore the involvement of complement in red blood cell 
homeostasis and the role of GPI-anchored proteins in the generation of microvesicles 
(MVs) in vivo. Detailed analysis of morphology, volume, and density of red blood cells with 
various CD59 expression levels from patients with PNH did not provide indications for a 
major aberration of the red blood cell aging process in patients with PNH. However, our 
data indicate that the absence of GPI-anchored membrane proteins affects the composition 
of red blood cell-derived microvesicles, as well as the composition and concentration of 
platelet-derived vesicles. These data open the way toward a better understanding on the 
pathophysiological mechanism of PNH and thereby to the development of new 
treatment strategies.
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INTRODUCTION
Paroxysmal nocturnal hemoglobinuria (PNH) is a highly debilitating disease that is characterized 
by intravascular hemolysis, arterial, and venous thrombosis (Malato et  al., 2012; Peacock-
Young et  al., 2018) and a variety of symptoms related to smooth muscle dystonia (DeZern 
and Brodsky, 2015). PNH is a rare disease with an incidence of 1–2 per 1,000,000 persons 
per year and is frequently associated with bone marrow failure such as aplastic anemia 
(Clemente et  al., 2018). PNH is caused by clonal expansion of multipotent hematopoietic 
stem cells with somatic mutations in the PIGA gene. PIGA encodes for an enzyme that is 
critical in the synthesis of the first intermediate in the pathway of glycosylphosphatidylinositol 
(GPI) anchors. (Takeda et  al., 1993; DeZern and Brodsky, 2015) As a consequence, the 
absence of PIGA activity results in hematopoietic cells that are deficient in GPI-anchored 
proteins. In RBCs, the absence of the GPI-anchored proteins decay-accelerating factor (DAF; 
Freitas Leal et al. Erythrocyte Homeostasis and Vesiculation in Patients With PNH
Frontiers in Physiology | www.frontiersin.org 2 May 2019 | Volume 10 | Article 578
CD55) and membrane inhibitor of reactive lysis (MIRL; CD59) 
that protect against complement-mediated lysis renders red 
blood cells (RBCs) highly vulnerable to intravascular hemolysis 
(Risitano and Rotoli, 2008; Brodsky, 2014). This results not 
only in anemia but also in the release of free hemoglobin 
and iron, which catalyzes the generation of reactive oxygen 
species and subsequent NO depletion and vasoconstriction 
(Kahn et  al., 2013; Rapido, 2017). For untreated patients, 
thrombosis is the most common cause of death (Hill et  al., 
2013; Griffin and Munir, 2017).
The monoclonal antibody eculizumab is the most effective 
drug used in PNH (Brodsky, 2009). Eculizumab blocks the 
cleavage of C5 by the C5 convertase into C5b and thereby 
inhibits the formation of the terminal membrane attack complex 
(MAC) C5b-9 and consequent hemolysis of abnormal RBCs. 
This reduces RBC destruction and transfusion requirements 
(Carroll and Sim, 2011; Risitano, 2012; Bayly-Jones et  al., 
2017). Nevertheless, the opsonizing effects of activated 
complement factors such as C3d may induce RBC phagocytosis 
(Risitano et  al., 2009; DeZern and Brodsky, 2015).
At present, the mechanism(s) responsible for clonal 
expansion during hematopoiesis and the variable clinical 
manifestations of the disease have only partially been elucidated 
(Hill et  al., 2017), but increased removal of RBC may 
contribute to the pathophysiology of PNH (Risitano and 
Rotoli, 2008). RBC homeostasis is dependent on the generation 
of young and removal of aged RBCs. The latter process is 
initiated by binding of senescent cell-specific IgG, the 
appearance of molecules that may trigger pathological reactions, 
such as immunoreactive epitopes on damaged membrane 
proteins, and exposure of phosphatidylserine (PS) in the 
outer leaflet of the lipid bilayer, all leading to phagocytosis 
(Bosman et  al., 2008; Dinkla et  al., 2014; Klei et  al., 2017). 
From biophysical, immunochemical, proteomic, and 
metabolomic studies, a molecular picture of the pathways 
involved in the normal aging and removal process of RBCs 
has emerged: oxidative damage-induced, high-affinity binding 
of hemoglobin to the cytoplasmic domain of band 3, activation 
of Ca2+-permeable channels, phosphorylation-controlled 
alterations in morphology and metabolism affecting ATP 
production and redox status, degradation of band 3 and/or 
aggregation of band 3 fragments, binding of IgG, and 
microvesicle (MV) generation (Ferru et  al., 2011; Zolla and 
D’Alessandro, 2012; Bosman, 2016). Physiological anti-band 
3 IgG has been reported to have a high affinity for dimeric 
C3b, thereby linking RBC phagocytosis to complement 
activation (Lutz and Bogdanova, 2013).
During physiological RBC aging, there is a small decrease 
in the content of GPI-anchored DAF and MIRL (Willekens 
et al., 2008), and in the content and activity of acetylcholinesterase 
(AChE), another GPI-anchored protein (Willekens et  al., 2008; 
Freitas Leal et  al., 2017). The latter observation suggests that 
the activities of DAF and/or MIRL might also decrease in healthy 
individuals and thereby contribute to complement-mediated 
opsonization and removal of old RBCs. AChE is increased in 
microvesicles, suggesting that changes in the distribution of 
GPI-anchored proteins in microdomains are associated with 
microvesicle (MV) generation (Salzer and Prohaska, 2001; Freitas 
Leal et al., 2017). As a consequence, the absence of GPI-anchored 
proteins may affect the microvesiculation process. Indeed, some 
data indicate that microvesiculation of RBCs and platelets may 
be  impaired in PNH patients (Whitlow et  al., 1993). Also, it 
has been shown that activated complement induces the massive 
formation of vesicles with a strong pro-coagulant activity 
(Ninomiya et  al., 1999). Thus, the absence of GPI-anchored 
proteins may have a pronounced effect on RBC morphology, 
function, and survival (Whitlow et al., 1993). In addition, exposure 
of the pro-coagulant and removal signal PS, which is in general 
associated with abnormal membrane organization and vesiculation 
in damaged or stressed, but not in aged RBCs (Bosman et  al., 
2008), has been reported to be  increased in RBCs of PNH 
patients (Sato et  al., 2010).
Here, we  have selected a number of aging-associated 
parameters from this current knowledge of the molecular 
mechanisms involved in physiological RBC homeostasis 
(Bosman et al., 2008, 2012; Lutz and Bogdanova, 2013; Bosman, 
2016; Freitas Leal et  al., 2018) that might be  relevant for the 
pathophysiology of PNH, in order to explore the effect of 
the absence of GPI-linked proteins on RBC structure, function, 
aging, and removal in vivo. Our data, obtained from PNH 
patients with various clone sizes and following various treatment 
regimes, indicate no significant effects of the absence of 
GPI-linked proteins on RBC turnover but emphasize the 
heuristic value of more, detailed studies on the origin, 
composition, and activity of RBC-derived and platelet-
derived microvesicles.
MATERIALS AND METHODS
Red Blood Cell Sampling
Blood was collected by venipuncture from healthy volunteers 
and 15 patients after obtaining written informed consent, 
and using EDTA as anticoagulant, following the guidelines 
of the local medical ethical committee (CMO regio Arnhem 
Nijmegen) and in accordance with the Declaration of Helsinki. 
Leukocytes and platelets were removed as described before 
using Ficoll-Paque (Freitas Leal et al., 2017). The time between 
blood collection, fractionation, and analysis was identical 
for all samples.
Red Blood Cell Fractionation and 
Microscopic Analysis
RBCs were fractionated according to cell density using 
discontinuous Percoll gradients ranging from 40% Percoll 
(1.060  g/ml) to 80% Percoll (1.096  g/ml) as described before 
(Willekens et  al., 2008; Freitas Leal et  al., 2017). The various 
RBC fractions were isolated and washed three times with 
Ringer’s solution (Freitas Leal et  al., 2017) by repeated 
centrifugation for 5 min at 400 g before analysis. RBC morphology 
was analyzed using a TCS SP5 confocal laser scanning microscope 
(Leica Microsystems, Mannheim, Germany) as described before 
(Cluitmans et  al., 2015).
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Isolation and Characterization of 
Microvesicles From Plasma
Microvesicles (MVs) were isolated from the platelet-rich plasma 
(PRP) obtained after differential centrifugation as described 
before (Dinkla et  al., 2012, 2013, 2016).
Flow Cytometry Analysis
Classification of the RBCs according to PNH type was 
performed by flow cytometry using FITC-labeled CD235a 
(clone KC16, 1:100, Beckman Coulter, Fullerton, CA, USA) 
and PE-labeled CD59 (clone MEM43, 1:400, IQ products, 
Groningen, the Netherlands) as described before (Sutherland 
et al., 2015). PNH RBCs were classified based on CD59 content 
in type III (complete GPI-deficiency), type II (partial 
GPI-deficiency), and type I (normal expression) cells (Sutherland 
et al., 2015). APC-labeled CD71 (clone CY1G4, 1:200, Biolegend, 
San Diego, California, USA) was combined with PE-labeled 
CD59 to evaluate the percentage of reticulocytes per PNH 
type. FITC-labeled anti-C3c (1:200, Abcam, Cambridge, UK) 
and APC-labeled anti-C3d (1  μg/million cells, Assay Pro, St. 
Louis, Missouri, USA) were combined with PE-labeled CD59 
to evaluate the degree of opsonization per PNH type. Staining 
of band 3 with eosin-5′ maleimide (EMA, Thermo Fisher 
Scientific, Landsmeer, the Netherlands) was performed by 
incubating 1 million RBCs with 25  μl of EMA (0.5  mg/ml 
in Ringer’s solution) in the dark at RT for 15  min. (Cobb 
and Beth, 1990; Crisp et  al., 2011). After staining, RBCs were 
washed three times with Ringer’s solution and analyzed by 
flow cytometry [FACSCalibur instrument (BD Biosciences, 
Franklin Lakes NJ, USA)] using CELLQuest software (BD 
Biosciences). Data were analyzed with FlowJo cell analysis 
software v.10 (FlowJo, LLC, Ashland, OR) using 200,000 events. 
Microvesicle analysis was performed using mixtures of 
PE-labeled CD59 (1:400), FITC-labeled CD235a (1:100), and 
PE/Cy5-labeled CD41 (1:10) by flow cytometry as previously 
described (Dinkla et al., 2012, 2013). Sulfate latex microspheres 
(0.9 μm, Invitrogen, Carlsbad CA, USA) and washed Flow-Count 
calibration beads (Beckman Coulter, Brea CA, USA) were 
used for quantification (Dinkla et  al., 2012). Microvesicles 
were classified based on CD59 positivity in CD59-negative 
(complete GPI-deficiency), low CD59 (partial GPI-deficiency), 
and wild type (normal expression).
Comparisons and Statistical Analyses
The exclusion criteria for the PNH patients were other 
hematological comorbidities besides aplastic anemia and having 
received a red blood cell transfusion within a period of 3 
months before analysis. For most analyses, we  compared 
PNH patients with control donors and PNH patients being 
treated with eculizumab with patients without eculizumab. 
Differences between groups were determined using a two-way 
ANOVA test. Non-parametric t-tests or one-way ANOVA 
tests were used to analyze differences between control and 
PNH samples. Wilcoxon matched pair tests were used to 
analyze differences between the various RBC fractions inside 
the groups, and the Fisher LSD test was used to compare 
controls and patient samples. Two-sided p’sless than 0.05 
were used to determine statistical significance. Relations 
between the various parameters were estimated using the 
Pearson correlation coefficient.
RESULTS
RBC Morphology and Phenotype
During aging in vivo and in vitro, RBCs undergo a series of 
morphological changes that result in the appearance of deformed, 
mostly spherocytic cells. Semi-quantitative analysis of these 
changes has been shown to be informative on RBC hemostasis 
and on the relationship between morphology, deformability, 
and survival (Cluitmans et  al., 2015). Microscopic analysis of 
RBCs from patients with PNH showed a tendency to a decrease 
in the numbers of cells with the regular discocyte form and 
a concomitant increase in the numbers of echinocyte-like and 
otherwise misshapen cells, especially in the densest cell fractions 
(Figure 1A). The majority of the patients’ RBCs were type 
I according to CD59 expression levels (Figure 1B), and we found 
no differences in the percentages of type II and type III cells 
between the various Percoll layers (Figure 1C). Treatment 
with eculizumab did not result in significant differences in 
CD59-deficient cells (Figure 1D).
Membrane/Band 3 Content  
(Eosine 5′-Maleimide)
RBC aging is accompanied by changes in membrane organization 
that are associated with the appearance of removal signals and 
with the loss of cell membrane. Especially, changes in the 
integral membrane protein band 3 play a pivotal role in the 
generation of senescence-specific antigens, in the interaction 
between lipid bilayer and cytoskeleton, and in the generation 
of microvesicles (Willekens et  al., 2008; Bosman et  al., 2012; 
Lutz and Bogdanova, 2013; Freitas Leal et  al., 2018). The 
amount of binding of the band 3 probe eosine 5′-maleimide 
(EMA) is mostly a sensitive marker of band 3 content, but 
also of Rh, Rh glycoprotein, and CD47, and/or of the loss of 
membrane (Cobb and Beth, 1990; Huisjes et  al., 2018). Flow 
cytometric analysis of the binding of EMA showed a higher 
EMA signal in all RBC fractions from two different PNH 
patients tested, independent of cell density and treatment 
(Figure  2). There was no significant difference in the density-
associated decrease between control donors or any of the PNH 
patients. Also, there was no statistically significant correlation 
between EMA fluorescence and the RBC size (forward scatter) 
in the RBC fractions of controls and PNH patients taken 
together (r  =  0.31, p  =  0.18, N  =  20).
Complement Deposition (C3c and C3d)
Activation of complement may lead to deposition of complement 
fragments on RBC through the CR1 receptor, and the 
presence of C3b fragments induces phagocytosis of eculizumab-
treated, CD59-negative RBCs in vitro (Lin et  al., 2015). 
We  therefore also probed for the presence of C3c and C3d 
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A B
FIGURE 2 | Eosin 5′-maleimide Mean Fluorescence Intensity (MFI) of RBC fractions. (A) RBCs of PNH patients (N = 2) and of control healthy donors (N = 7) of 
various Percoll fractions were stained with eosin 5′-maleimide (EMA). The degree of staining is expressed as the mean fluorescence intensity (MFI). (B) EMA MFI of 
RBCs of a PNH patient being treated with (T) and without (NT) eculizumab, separated according to density. Ctrl, healthy donors (N = 7). The samples were analyzed 
as described before (see Materials and Methods). #Significantly different from control (p < 0.05). U, unseparated; f1, f3, f5, fractions of increasing density isolated by 
Percoll density separation (Materials and Methods).
A
B
C
D
FIGURE 1 | RBCs morphology and phenotype of PNH patients. (A) Percentage of discocytes per Percoll fraction in PNH patients (N = 5) and healthy control 
donors (N = 5); (B) bright field and fluorescence images of anti-CD59-Alexa 647 stained RBCs from a healthy subject and a PNH patient, showing CD59 density; 
(C) RBCs of PNH patients (N = 9) were separated according to density and analyzed by flow cytometry regarding their CD59 content (type I, II, and III); (D) RBCs of 
PNH patients being treated with eculizumab (T; N = 5) and non-treated PNH patients (NT; N = 4) separated according to density and analyzed by flow cytometry 
according to their CD59 content (type I, II, and III). #Significantly different from type I in the same Percoll fraction (p < 0.05). U, unseparated; f1, f3, f5, fractions of 
increasing density isolated by Percoll density separation (Materials and Methods).
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in density-separated RBCs. For both proteins, we  observed 
a tendency to an increase in the percentage of positive cells 
with cell density (Figure 3). Thus, the content of RBC-bound 
C3c as well as C3d may increase with cell age, also on type 
I  RBCs with a normal content of CD59 (Figure 3). These 
findings are in agreement with previous indications for the 
involvement of complement in phagocytosis in vitro (Lutz, 
2004; Arese et al., 2005). We found no significant correlations 
between these parameters and treatment with eculizumab 
(data not shown).
Reticulocytes
Aberrant RBC structure resulting in a decreased mean life 
and leading to anemia is, in many cases, compensated by 
increased erythropoiesis, as indicated by changes in the size 
of the reticulocyte fraction. The hematological data show a 
large variability in the size of the reticulocyte fractions of 
our patients, without any significant correlation with other 
patient variables, although most eculizumab-treated patients 
had higher reticulocyte numbers than the patients without 
eculizumab (Supplementary Table 1). Flow cytometric analysis 
of the RBCs of a few PNH patients showed similar data, 
also without significant differences between donors or RBC 
fractions (Figures  4A,B). In general, most reticulocytes were 
found in the lightest density fractions upon Percoll separation, 
i.e., fraction 1 (Figure 4A), as shown before for healthy 
individuals (Willekens et  al., 2008). The fraction of type III, 
CD59-lacking reticulocytes was considerably higher than the 
other types (Figure 4C), which may reflect a disturbed 
differentiation and/or maturation process in the absence of 
GPI-linked proteins (Sato et  al., 2010).
Microvesicles
Microvesicle generation is an integral part of the physiological 
RBC aging process, and changes in microvesicle concentration 
as well as composition occur in patients with disturbed RBC 
homeostasis (Freitas Leal et  al., 2018). We  found no significant 
differences in the concentrations of RBC-derived microvesicles 
between PNH patients and controls (Figure 5A). However, the 
concentration of PS-negative microvesicles in the plasma of 
PNH patients was higher than in the plasma of control donors 
(Figure 5B). The concentration of CD59-high RBC-derived 
microvesicles was higher than that of the other types in the 
plasma of control donors but not in the plasma of PNH patients 
(Figure 5C). Platelet-derived microvesicle concentrations were 
much higher in the plasma of PNH patients than in controls 
(Figure 5D), both the PS-positive and the PS-negative 
microvesicles (Figure 5E). Remarkably, almost all platelet-derived 
A B
FIGURE 3 | Complement deposition on density-separated RBCs. (A) Percentage of C3c-positive RBCs in the PNH RBC population divided per CD59 content 
(type I, II, and III) per density (Percoll fraction; N = 2); (B) percentage of C3d-positive RBCs in the PNH RBC population according to CD59 content (type I, II, and III) 
per Percoll fraction (type I, II, and III; N = 3). The samples were analyzed as described before (see Materials and Methods). U, unseparated; f1, f3, f5, fractions of 
increasing density isolated by Percoll density separation (Materials and Methods).
A B C
FIGURE 4 | Reticulocytes in patients with PNH. (A) Percentage of CD71-expressing RBCs from the blood of PNH patients (N = 2) and healthy control  
donors RBCs (N = 4) of various Percoll fractions after staining with APC-labeled CD71; (B) percentage of APC-CD71-positive RBCs of a PNH patient being  
treated with eculizumab (T), a non-treated PNH patient (NT), and healthy control donors in the reticulocyte-enriched Percoll fraction 1 (Ctrl; N = 4); (C) percentage of 
APC-CD71-positive RBCs in the PNH RBC population per CD59 content (type I, II, and III) in fraction 1 (N = 2). The samples were analyzed as described before  
(see Materials and Methods). U, unseparated; f1, f3, f5, fractions of increasing density isolated by Percoll density separation (Materials and Methods).
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microvesicles were devoid of CD59, including those from the 
plasma of control donors (Figure 5F). We observed no statistically 
significant correlations between the numbers of RBC-derived 
and platelet-derived vesicles (r  =  −0.40, p  =  0.28, N  =  9).
DISCUSSION
RBC Aging and Generation of 
Microvesicles
Red blood cells of PNH patients lack the key GPI-anchored 
membrane proteins that protect against activated complement. 
We  postulated that this change in membrane composition has 
a more wide-spread effect on membrane organization and 
thereby on various aspects of RBC homeostasis. The most 
obvious aspects derive from the role of complement in removal 
of senescent RBCs and the involvement of GPI-linked proteins 
in microdomain-associated generation of microvesicles (Lutz, 
2004; Lutz and Bogdanova, 2013; de Back et  al., 2014; Saha 
et al., 2016; Pollet et al., 2018). In this exploratory study, we did 
not find significant indications for a pronounced alteration of 
RBC homeostasis in patients with PNH, as based on cell volume, 
cell density, and morphology or on clinical hematology 
parameters, including LDH values (Supplementary Table  1). 
Thus, in most of our patients, the lack of GPI-anchored proteins 
does not seem to cause a major disturbance of the physiological 
RBC aging mechanisms.
Nevertheless, there were clear differences related to 
membrane composition and microvesicle formation. The EMA 
measurements showed significant differences between the 
RBCs of PNH patients and of control donors (Figure 2). 
The tendency to a density-associated decrease in EMA staining 
might be  due to loss of band 3 and/or membrane with 
aging by vesiculation, both in RBCs from control donors 
and from PNH patients. This has been postulated before 
for physiological aging in vivo (Willekens et  al., 2008). 
However, the absence of a statistically significant correlation 
between EMA fluorescence and the RBC size, based on the 
cytometer parameter forward scatter, suggests that in the 
RBCs from PNH patients, the band 3 protein content is not 
a direct function of cell size. EMA staining is affected by 
changes in band 3 conformation and membrane organization 
as well (e.g., Cobb and Beth, 1990; Huisjes et  al., 2018). 
Combined with the considerable fractions of PS-negative and 
CD59-lacking microvesicles in the blood of PNH patients 
(Figure 5), these data indicate that the organization of the 
RBC membrane, as well as the mechanism of microvesicle 
generation, are altered by the absence of GPI-linked proteins. 
This may be  a direct effect, but also the consequence of the 
deposition of C3b. The latter not only affects lateral mobility 
of CD59 and band 3 molecules but also membrane viscosity 
and deformability (Karnchanaphanurach et  al., 2009; Glodek 
et  al., 2010). Our in vivo data support the involvement of 
GPI-linked proteins in microvesicle formation during RBC 
aging in vitro (Salzer et  al., 2008; Freitas Leal et  al., 2017). 
The differences in mechanisms leading to the generation of 
microvesicles with and without PS at their outside remain 
to be  established, as well as the effect on biological activity. 
A B C
D E F
FIGURE 5 | Microvesicle numbers and composition in the blood of patients with PNH. (A) Concentration per microliter (MV/μl) of RBC-derived, CD235a-positive 
microvesicles in the blood of PNH patients (N = 9) and control healthy donors (N = 6); (B) concentration of RBC-derived microvesicles in the blood of PNH  
patients (N = 9) and control healthy donors (N = 3), distinguished according to their reactivity to Annexin V (phosphatidylserine-positive (PS+) or negative (PS−);  
(C) RBC-derived microvesicles were categorized into wild type, CD59-low and CD59-negative PNH, N = 9; Ctrl, N = 3), as described for RBCs (Materials and 
Methods); (D) concentration of CD41-positive, platelet-derived microvesicles in the blood of PNH patients (N = 9) and control healthy donors (N = 6);  
(E) concentration of platelet-derived microvesicles according their reactivity to Annexin V (PS+ or PS−; PNH, N = 9; Ctrl, N = 3); (F) platelet-derived microvesicles 
were categorized into wild type, CD59-low and CD59-negative as described for RBCs and quantified and analyzed by flow cytometry as described before  
(PNH, N = 9; Ctrl, N = 3). #Significantly different from the other parameter (p < 0.05); *Significantly different from the patients’ samples (p < 0.05).
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Since PS exposure contributes to recognition and removal 
of microvesicles by macrophages (Willekens et  al., 2005), its 
absence may not only affect their pro-coagulant activity but 
also their lifespan. Fusion between microvesicles and RBCs 
may underlie the reported transfer between CD55 and CD59 
from normal RBCs to RBCs without these proteins (Sloand 
et  al., 2004). Thus, microvesicles generated by PNH RBCs 
may also fuse with normal RBCs, thereby affecting their 
membrane organization as well. Furthermore, increased levels 
of RBC-derived microvesicles may affect NO bioavailability 
(Said et  al., 2018) and induce activation of endothelial cells 
and tissue factor expression (Collier et  al., 2013), thereby 
contributing to the wide-spread thrombosis in patients 
with PNH.
Platelet Microvesicles and Thrombosis
Platelets without CD59 have been described to catalyze 
the rate of prothrombin conversion upon treatment with 
complement C5b-9 in vitro, and this was associated with 
an increase in microvesicle formation (Wiedmer et  al., 
1993). RBC-derived and platelet-derived, phosphatidylserine-
positive microvesicles have been reported to be increased 
approximately two-fold in the blood of PNH patients (Hugel 
et al., 1999). We found equal concentrations of RBC-derived 
microvesicles in the plasma of PNH patients and healthy 
donors, but much larger RBC-derived, phosphatidylserine-
negative microvesicle concentrations in the blood of PNH 
patients (Figure 5B), and larger concentrations of platelet-
derived vesicles (Figure  5D). In the plasma of eculizumab-
treated PNH patients, the numbers of RBC-derived vesicles 
were lower than in patients who had not been treated with 
eculizumab (Supplementary Figure S1). The absence of a 
statistically significant correlation between the concentrations 
of RBC-derived and platelet-derived microvesicles indicates 
that the absence of GPI-linked proteins affects microvesicle 
generation from RBCs and platelets through different 
mechanisms. Although in control donors, most platelets 
are CD59-positive (Jin et  al., 1997), almost all platelet-
derived microvesicles were CD59-negative (Figure 5). There 
were approximately equal concentrations of platelet-derived 
vesicles with and without PS at their surface (Figure 5E). 
These data strongly suggest that the absence of GPI-linked 
proteins does not only have a pronounced stimulatory effect 
on the generation of microvesicles but also on their 
composition. The latter may be  related to the presence of 
tissue factor and is likely to affect their function (Devalet 
et  al., 2014). Our recent finding that platelet-derived 
microvesicles can prevent differentiation of regulatory T-cells 
through P-selectin (Dinkla et  al., 2016) emphasizes their 
pivotal role in the pathophysiology of many diseases that 
may include PNH (Devalet et al., 2014). Although the name 
suggests otherwise, most platelet-derived microvesicles 
originate not from platelets, but from megakaryocytes in 
the bone marrow (Flaumenhaft et  al., 2009; Rank et  al., 
2010). It is not known how the absence of GPI-linked 
proteins affects megakaryocyte biology and/or platelet 
activation. These data support the importance of an extensive 
characterization of origin, composition, and biological activity 
of CD41-positive microvesicles. Such studies may help in 
establishing an urgently needed, robust marker of 
platelet activation.
CONCLUSION
The heterogeneity of the patient population and the concomitant 
small numbers available for statistical comparisons of all 
parameters preclude a robust answer on the question whether 
RBC aging is altered in patients with PNH. However, the 
combined results of the selected aging-associated parameters 
(Bosman et  al., 2008, 2012; Lutz and Bogdanova, 2013) do 
not reveal a major aberration of the physiological RBC aging 
process in patients with PNH. Remarkably, formation of 
microvesicles by RBCs is altered in patients with PNH. This 
is likely due to PNH-related differences in membrane 
organization that is associated with the absence of GPI-linked 
proteins. The conspicuous lack of phosphatidylserine exposure 
on many RBC-derived microvesicles in PNH patients may 
affect their time in the circulation as well as their contribution 
to hemostasis and thrombosis. In platelets, PNH-related 
processes seem not only to induce the appearance of large 
numbers of phosphatidylserine-negative microvesicles but 
also to cause excessive formation of microvesicles. Future 
investigations leading to a better understanding of the 
mechanisms underlying vesiculation, effect of vesiculation 
on RBC function and survival, and effect of the various 
microvesicles on thrombosis in patients with PNH may 
be  instrumental in developing new treatment strategies 
(Kulasekararaj et  al., 2019).
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SUPPLEMENTARY FIGURE S1 | Microvesicle numbers and composition in 
the blood of patients with PNH CD59 level and treatment. (A) Concentration 
(MV/μl) of CD235a-positive, RBC-derived microvesicles (MVs) in the blood of 
PNH patients who did not receive treatment (NT; N = 3), PNH patients who 
were treated with eculizumab (T; N = 6), and control healthy donors (N = 6);  
(B) concentration of RBC-derived microvesicles in the blood of PNH patients 
who did not receive treatment (NT; N = 3), PNH patients who were being 
treated with eculizumab (T; N = 6) and control donors (N = 6) according their 
reactivity to Annexin V (phosphatidylserine positive (PS+) or negative (PS−); (C) 
RBC-derived microvesicles in the blood of PNH patients who did not receive 
treatment (NT; N = 3), PNH patients who were being treated with eculizumab (T; 
N = 6) categorized in wild type, CD59-low and CD59-negative as described for 
RBCs (Materials and Methods); (D) concentration of platelet-derived 
microvesicles (CD41-positive) from the blood of PNH patients who did not 
receive treatment with eculizumab (NT; N = 3), PNH patients who were being 
treated with eculizumab (T; N = 6) and control healthy donors (N = 6); (E) 
concentration of platelet-derived microvesicles in the blood of PNH patients 
who did not receive treatment with eculizumab (NT; N = 3), PNH patients who 
were being treated with eculizumab (T; N = 6) and control healthy donors 
(N = 6), according their reactivity to Annexin V (PS+ or PS−); (F) platelet-derived 
microvesicles from the blood of PNH patients who did not receive treatment 
with eculizumab (NT; N = 3), PNH patients who were being treated with 
eculizumab (T; N = 6) were categorized in wild type, low CD59, and CD59-
negative as described for RBCs and quantified and analyzed by flow cytometry 
as described before (see Materials and Methods). #Significantly different from 
the other parameter in the same group (p < 0.05). *Significantly different 
between groups (p < 0.05).
SUPPLEMENTARY TABLE 1 | Clinical data of PNH patients. AA, PNH patient 
with aplastic anemia; N, PNH patient without hematological comorbidities; T, in 
treatment; NT, not in treatment; RBC, red blood cells (×1012/L); RBC CS (II/III), 
red blood cell clone size (type II and III); Hb, hemoglobin (g/dl); Ht, hematocrit 
(%); MCV, mean corpuscular volume (fl); MCH, mean corpuscular hemoglobin 
(pg); MCHC, mean corpuscular hemoglobin concentration (g/dl); RDW, red 
blood cell distribution width (%); Retic, reticulocytes (promille); RBC Tr, red 
blood cell transfusion in the last 3 months; Leuk, Leukocytes (×109/L); Gran 
CS., granulocytes clone size; Plt, platelet (×109/L); LDH, lactate dehydrogenase 
(U/L); −, not available. Reference values for healthy adults: RBC: for men, 4.7–
6.1 × 1012/L and for women, 4.2–5.4 × 1012/L; Hb: for men, 8.5–11 mmol/L and 
for women, 7.5–10 mmol/dl; Ht: for men, 0.4–0.54 and for women, 0.36–0.46; 
MCV: 80–96 fl; MCH: 1.7–2.1 fmol; MCHC: 19.3–22.5 mmol/L; RDW: 11.5–
14.5%; Retic: 8–26 promille; Leuk: 4.5–11 × 109/L; Plt: 150–400 × 109/L; LDH: 
135–225 U/L.
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